HIGHLIGHTS
SUMMARY
Given the recent passing of the 2022 FDA Moderinization Act 2.0 by the United_States Congress, this landscape is changing and will provide drug sponsors with the capacity to use alternative complex in_vitro models where suitable. Taken together, the above challenges have stimulated interest in developing more complex, yet easily manipulated, in_vitro models of human cancer to accelerate fundamental discovery science and therapeutic testing. Traditional in_vitro cell culturing involves 2D monolayers of cells grown on tissueculture-treated glass or hard plastic, and has been used for over 50 years to assess the effects of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.